精准医学时代EGFR突变阳性非小细胞肺癌的全程管理:学习型MDT体系的构建与优化OA

In the era of precision medicine,therapeutic strategies for epidermal growth factor receptor(EGFR)mutation-positive non-small cell lung cancer(NSCLC)have become increasingly advanced.However,conventional multidisciplinary team(MDT)models fail to address the demands of dynamic whole-course disease management.This review proposes an evolved learning-oriented MDT system for the standardized management of EGFR mutation-positive NSCLC.Grounded in evidence-based medicine,centered on expert decision-making,and supported by digital integration,this system enables the comprehensive evaluation of patients'individual characteristics,including performance status,psychosocial conditions,and economic affordability.This article elucidates the core management objectives and key PICO-style clinical questions for EGFR mutation-positive NSCLC across critical disease stages,including resect-able early-stage disease,stage Ⅲ disease,metastatic/oligoprogressive disease,and tyrosine kinase inhibitor-resistant disease.Based on updated quantitative clinical evidence,we develop a structured framework for the learning-oriented MDT system,covering a multidimensional collaborative structure,standardized node-based workflows,a full-cycle inf-ormation integration platform,quantita-tive evaluation indicators,and a closed-loop optimization mechanism.Notably,we propose a multicenter prospective randomized controlled trial design to validate the clinical efficacy of this system.This review analyzes the imple-mentation limitations and potential soc-ial impacts of the system and proposes phased optimization and mitigation stra-tegies.This work provides a theoretical framework and practical guidance for establishing a stand-ardized,precise,and humanistic whole-course management model for EGFR mutation-positive NSCLC.